Pharmacodynamic monitoring of BAY 43‐9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells

Abstract

These findings support the further development of flow cytometry applications to monitor signal transduction inhibitors during early phase clinical trials.